×
About 5,958 results

ALLMedicine™ Mantle Cell Lymphoma Center

Research & Reviews  1,625 results

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymp...
https://doi.org/10.1200/JCO.21.02321
Journal of Clinical Oncology : Official Journal of the Am... Giné E, de la Cruz F et. al.

Jan 15th, 2022 - The need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in combination with rituximab (IR) could obtain significant res...

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03571828

Jan 14th, 2022 - Evaluate the safety and tolerability of AMG 562 in adult subjects with DLBCL, MCL, or FL. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (e.g., recommended phase 2 dose [RP2D])

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
https://doi.org/10.1038/s41467-021-27853-w
Nature Communications; Wong DP, Roy NK et. al.

Jan 13th, 2022 - B cell-activating factor (BAFF) binds the three receptors BAFF-R, BCMA, and TACI, predominantly expressed on mature B cells. Almost all B cell cancers are reported to express at least one of these receptors. Here we develop a BAFF ligand-based chi...

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04930536

Jan 10th, 2022 - A prospective, multi-centre, phase IV clinical trial of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL). As per recommendation from Indian health autho...

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04659044

Jan 10th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the end of induction (EOI) complete response rate (CR) for treatment with the regimen of rituximab and hyaluronidase human + polatuzumab vedotin + venetoclax (RSC + Pola + Ven) in relapsed/refractory mantle cell l...

see more →

Guidelines  3 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines fo...
https://doi.org/10.1093/annonc/mdx223
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Campo E et. al.

Sep 9th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,

Non-Hodgkin's lymphomas, version 4.2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839265
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.

Sep 6th, 2014 - Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL case...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  130 results

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03571828

Jan 14th, 2022 - Evaluate the safety and tolerability of AMG 562 in adult subjects with DLBCL, MCL, or FL. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (e.g., recommended phase 2 dose [RP2D])

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04930536

Jan 10th, 2022 - A prospective, multi-centre, phase IV clinical trial of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL). As per recommendation from Indian health autho...

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04659044

Jan 10th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the end of induction (EOI) complete response rate (CR) for treatment with the regimen of rituximab and hyaluronidase human + polatuzumab vedotin + venetoclax (RSC + Pola + Ven) in relapsed/refractory mantle cell l...

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02736617

Jan 5th, 2022 - PRIMARY OBJECTIVE: I. Best overall response of complete response/partial response (CR/PR). SECONDARY OBJECTIVES: I. Toxicity defined as any adverse event (AE) grade 3 and higher. II. Progression free survival. EXPLORATORY/CORRELATIVE OBJECTIVES: I...

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01776840

Jan 3rd, 2022 - This is a randomized (individuals assigned to study treatment by chance), double blind (neither physician nor participant knows the treatment that the participant receives), placebo (an inactive substance that is compared with a drug to test wheth...

see more →

News  613 results

Ibrutinib/Rituximab Combo Represents Effective Chemo-Free Option for Elderly Patients with MCL
https://www.onclive.com/view/ibrutinib-rituximab-combo-represents-effective-chemo-free-option-for-elderly-patients-with-mcl

Jan 14th, 2022 - The combination of ibrutinib (Imbruvica) and rituximab (Rituxan) produced a high overall response rate (ORR) and durable survival in elderly patients with mantle cell lymphoma (MCL), according to data from a phase 2 ENRICH trial (NCT0180567) publi...

FDA Grants RMAT/Fast Track Designations to C-CAR039 for Relapsed/Refractory DLBCL
https://www.onclive.com/view/fda-grants-rmat-fast-track-designations-to-c-car039-for-relapsed-refractory-dlbcl

Jan 12th, 2022 - The FDA has granted a regenerative medicine advanced therapy (RMAT) designation and a fast track designation to C-CAR039 for use as a potential therapeutic option in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).1 A n...

Dr. Heyman on the Evolution of BTK Inhibitors in Relapsed/Refractory MCL
https://www.onclive.com/view/dr-heyman-on-the-evolution-of-btk-inhibitors-in-relapsed-refractory-mcl

Jan 5th, 2022 - Benjamin Heyman, MD, assistant clinical professor, Medicine, hematologist, Moores Cancer Center, University of California, San Diego Health, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma (MCL). The introd...

Expansion Cohort Explores Efficacy of Novel Treatment for Waldenström Macroglobulinemia
https://www.onclive.com/view/expansion-cohort-explores-efficacy-of-novel-treatment-for-waldenstr-m-macroglobulinemia

Jan 5th, 2022 - Treatment options for patients with Waldeström macroglobulinemia (WM) are often derived from those developed for patients with multiple myeloma and other low-grade lymphomas. Patients with WM are relatively rare. Their disease is defined as lympho...

Dr. Riedell on the Effects of Time to Relapse on Outcomes in MCL
https://www.onclive.com/view/dr-riedell-on-the-effects-of-time-to-relapse-on-outcomes-in-mcl

Dec 21st, 2021 - Peter Riedell, MD, assistant professor of medicine, University of Chicago Medicine, discusses the effects of time to relapse on outcomes in mantle cell lymphoma (MCL). Findings from an analysis examining the effect of time to relapse on overall...

see more →